KALA vs VTRS: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. KALA and VTRS share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined KALA and VTRS exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

KALA BIO, Inc. (formerly Kala Pharmaceuticals) is a Nasdaq-listed company that spent years as a clinical-stage biopharmaceutical developer focused on eye diseases. Its lead program, KPI-012, was a mesenchymal stem cell secretome (MSC-S) therapy being tested for persistent corneal epithelial defect (PCED), a serious condition where the cornea fails to heal.

Full KALA guide

Viatris was created in November 2020 by merging Mylan with Pfizer's Upjohn business, uniting a large generics and biosimilars operation with a portfolio of well-known, off-patent branded drugs such as Lipitor, Norvasc, Viagra, and EpiPen. It sells across more than 165 countries and reports through a global commercial footprint that spans developed and emerging markets, with a business mix of generics, established brands, and a smaller but growing specialty and pipeline component. Because most of its revenue comes from mature, off-patent medicines, Viatris behaves like a value stock: steady cash generation, a modest valuation multiple, and slow top-line growth rather than the rapid expansion of a patent-protected innovator.

Full VTRS guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• KALA drivers: The AI-platform pivot (Researgency); Survival, cash runway, and dilution.
• VTRS drivers: Cash flow, debt reduction, and the dividend; Pivot from generics giant to specialty and pipeline.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The risks here are severe and largely existential. For VTRS, the biggest risk is structural: most of Viatris's revenue comes from mature, off-patent medicines facing constant price erosion and competition, which has produced years of flat-to-declining sales and makes growth hard to generate.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick KALA if you believe its drivers more; VTRS if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the KALA and VTRS guides.

KALA. These figures are approximate, tied to the asOf date, and should be verified against the company's latest filings before acting. Traditional valuation multiples do not apply to a pre-revenue, post-failure biotech: there are no earnings to value, and the market cap reflects a bet on the unproven AI pivot, any residual asset value, and cash net of a high burn rate. In distressed situations like this, dilution risk and going-concern uncertainty matter far more than any earnings multiple, and small news items can move the stock violently.

VTRS. Figures are approximate and tied to the asOf date; verify live numbers (current revenue, guidance, adjusted and GAAP EPS, dividend, and debt levels) before acting. Viatris trades on a low multiple typical of a slow-growth value stock, and its adjusted EPS looks much healthier than its GAAP result because large non-cash impairments hit the reported bottom line. The gap between adjusted and GAAP earnings, plus how much of the low multiple reflects genuine value versus stagnant revenue, is the crux of the debate on the stock.

Headline figures (approximate, Jul 2026): KALA shows revenue Effectively pre-revenue; no meaningful product revenue after KPI-012's discontinuation, and the AI pivot has yet to generate scaled sales, net loss (fy2025) ~$27 million, typical of a clinical-stage biotech spending on R&D and operations, accumulated deficit ~$695 million, reflecting years of drug-development losses, cash position Small, reported around $7-8 million for late 2025, with management indicating runway only into early 2027; VTRS shows revenue (fy2025) ~$13.9 to $14.3 billion, down from ~$14.7 billion in 2024, partly due to divestitures, fy2026 revenue guidance ~$14.45 to $14.95 billion (reaffirmed), fy2026 adjusted eps guidance ~$2.33 to $2.47, fy2025 gaap result Large net loss (~$3.5 billion) driven mainly by non-cash goodwill impairment.

KALA and VTRS are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined KALA and VTRS exposure against your real portfolio. It is not an investment adviser.